Cardiol Therapeutics Inc. (CRDL)
NASDAQ: CRDL · Real-Time Price · USD
1.560
-0.090 (-5.45%)
At close: Nov 20, 2024, 4:00 PM
1.600
+0.040 (2.56%)
Pre-market: Nov 21, 2024, 7:00 AM EST
Cardiol Therapeutics Income Statement
Financials in millions CAD. Fiscal year is January - December.
Millions CAD. Fiscal year is Jan - Dec.
TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
Revenue | - | - | - | 0.08 | - | - | |
Gross Profit | - | - | - | 0.08 | - | - | |
Selling, General & Admin | 24.49 | 15.56 | 22.37 | 27.87 | 10.09 | 4.95 | |
Research & Development | 13.82 | 14.22 | 18.96 | 10.87 | 10.6 | 3.53 | |
Operating Expenses | 38.32 | 29.79 | 41.34 | 38.74 | 20.69 | 11.89 | |
Operating Income | -38.32 | -29.79 | -41.34 | -38.66 | -20.69 | -11.89 | |
Interest Expense | - | - | - | - | - | -0 | |
Interest & Investment Income | 1.33 | 2.04 | 1.24 | 0.11 | 0.08 | 0.25 | |
Currency Exchange Gain (Loss) | 0.01 | -0.71 | 2.76 | 1.89 | -0.03 | -0.1 | |
Other Non Operating Income (Expenses) | 0.83 | 0.33 | 6.41 | 5.03 | 0.01 | -1.94 | |
Pretax Income | -36.14 | -28.13 | -30.93 | -31.64 | -20.64 | -13.68 | |
Net Income | -36.14 | -28.13 | -30.93 | -31.64 | -20.64 | -13.68 | |
Net Income to Common | -36.14 | -28.13 | -30.93 | -31.64 | -20.64 | -13.68 | |
Shares Outstanding (Basic) | 68 | 64 | 63 | 43 | 30 | 26 | |
Shares Outstanding (Diluted) | 68 | 64 | 63 | 43 | 30 | 26 | |
Shares Change (YoY) | 5.66% | 3.13% | 44.61% | 44.77% | 15.63% | 67.97% | |
EPS (Basic) | -0.53 | -0.44 | -0.49 | -0.73 | -0.69 | -0.53 | |
EPS (Diluted) | -0.53 | -0.44 | -0.49 | -0.73 | -0.69 | -0.53 | |
Free Cash Flow | -25.96 | -25.24 | -27.3 | -23.55 | -9.17 | -11.8 | |
Free Cash Flow Per Share | -0.38 | -0.39 | -0.44 | -0.54 | -0.31 | -0.46 | |
Gross Margin | - | - | - | 100.00% | - | - | |
Operating Margin | - | - | - | -49091.93% | - | - | |
Profit Margin | - | - | - | -40170.45% | - | - | |
Free Cash Flow Margin | - | - | - | -29904.22% | - | - | |
EBITDA | -37.98 | -29.59 | -41.16 | -38.44 | -20.46 | -11.77 | |
D&A For EBITDA | 0.34 | 0.2 | 0.18 | 0.22 | 0.23 | 0.13 | |
EBIT | -38.32 | -29.79 | -41.34 | -38.66 | -20.69 | -11.89 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.